Medicine
Orbactiv 400 mg powder for injection
Orbactiv 400 mg powder for injection is a prescription medicine containing Oritavancin for intravenous use, marketed by Melinta Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Storage ORBACTIV is supplied as a sterile white to off-white lyophilized…
Key facts
- Active ingredient (INN)
- Oritavancin
- Brand
- Orbactiv
- Strength
- 400 mg
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 3 vials
- Marketing authorisation holder
- Melinta Therapeutics
- Manufacturer
- Melinta Therapeutics
- Origin register
- US FDA, United States
- Storage
- Storage ORBACTIV is supplied as a sterile white to off-white lyophilized powder in single-dose clear glass vials containing 400 mg of oritavancin (NDC 70842-140-01), packaged in a carton of 3 vials (NDC 70842-140-03).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J01XA05 Oritavancin
- HS code (indicative)
- 3004.20Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 September 2014
- Identifiers
- RxCUI 1547615, 1547620DailyMed set ID ff09a726-9f9b-4e30-b509-396781293220NDC 70842-140Application NDA206334
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 3 vial, glass in 1 carton / 1 injection, powder, lyophilized, for solution in 1 vial, glass | 70842-140-03 | Melinta Therapeutics | 1 September 2014 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Oritavancin
Clinical summary
Oritavancin is a lipoglycopeptide antibacterial indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms, among other approved uses. MedsAcross supplies Oritavancin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about OritavancinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Orbactiv prescribing information (Melinta Therapeutics) · U.S. National Library of Medicine, DailyMed
- Tenkasi (previously Orbactiv): European public assessment report (EPAR) · European Medicines Agency
Need Orbactiv 400 mg powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.